Affiliation:
1. National Medical Research Centre of Oncology n. a. N. N. Petrov
2. North-Western State Medical University n. a. I. I. Mechnikov
Abstract
The use of antiangiogenic drugs in a single mode or in combination with immunotherapy in disseminated renal cell carcinoma has made it possible to achieve significant results in the therapy of the metastatic process. The flip side of effective therapy is the development of adverse events. An increase in blood pressure is one of the most frequent complications of antiangiogenic drug therapy with a frequency of up to 80 %.
Subject
Materials Chemistry,Economics and Econometrics,Media Technology,Forestry
Reference32 articles.
1. Global Cancer Observatory (iarc.fr).
2. Edited by A. D. Kaprin, VSOSH. The state of oncological care to the population of Russia in 2021 (2022).
3. Gloeckler Ries, L. A., Reichman, M. E., Lewis, D. R., Hankey, B. F. & Edwards, B. K. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8, 541–52 (2003).
4. Gloeckler Ries L. A., Reichman M. E., Lewis D. R., Hankey B. F. & Edwards B. K. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 8, 541–52 (2003).
5. Vaishampayan U. et al. The Effect of Targeted Therapy on Overall Survival in Advanced Renal Cancer: A Study of the National Surveillance Epidemiology and End Results Registry Database. Clin Genitourin Cancer 12, 124–129 (2014).